IFF earnings analysis
What we found in IFF's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
IFF delivered healthy underlying Q2 continuing-operations momentum: revenue increased 2% reported and 6% on a comparable currency-neutral basis, with gross margin up 80 basis points to 43.7% and all three continuing segments growing. However, reported profitability was weak, with GAAP diluted EPS declining to $0.20 from $2.33 and continuing-operations EPS declining to $0.13 from $2.14, reflecting a difficult comparison to a $488 million prior-year debt-extinguishment gain as well as a 48.4% tax rate and $71 million of regulatory costs. Cash generation strengthened materially, but the investment case remains tied to execution of the Food Ingredients divestiture and associated capital-return program.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Core sales growth across all segments
- Continuing-operations sales rose $35 million, or 2%, to $1.954 billion; comparable currency-neutral sales increased 6%. All three continuing segments grew, led by Scent at 10%.
- Gross margin expanded 80 basis points
- Gross margin expanded 80 basis points year over year to 43.7%, as gross profit increased $29 million to $853 million. Management cited volume, productivity gains, and tariff refunds.
- Operating profitability improved
- Operating profit rose 11% to $158 million and operating margin increased 70 basis points to 8.1%. Continuing adjusted operating EBITDA increased to $408 million from $399 million, while its margin held at 20.9% versus 20.8%.
- Operating cash flow rose $311 million
- Six-month operating cash flow increased to $679 million from $368 million. The improvement reflected lower working capital, principally inventories and payables, plus a smaller incentive-compensation payout.
- Liquidity and covenant headroom remain solid
- Leverage remains within covenant capacity: total debt was $5.735 billion, cash was $569 million, and net debt-to-credit-adjusted EBITDA was 2.51x; there were no borrowings on the $2.0 billion revolver.
- Enhanced $2.5 billion shareholder return plan
- The board authorized a $2.5 billion enhanced share repurchase program, including a $500 million accelerated repurchase expected in the second half of 2026. The company repurchased 482,528 shares for $74.17 per share in the quarter.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- GAAP EPS declined sharply year over year
- GAAP diluted EPS fell to $0.20 from $2.33, while continuing-operations diluted EPS fell to $0.13 from $2.14. The prior-year comparison included a $488 million gain on debt extinguishment, but current earnings also absorbed a $27 million held-for-sale asset loss.
- Tax rate and regulatory costs pressure earnings
- The effective tax rate increased to 48.4% from negative 25.6%, driven by non-deductible regulatory costs, prior-year entity realignment effects, divestitures, and earnings mix. Regulatory costs were $71 million, versus $53 million a year earlier.
- Divestiture execution remains material
- Food Ingredients and SCL were classified as discontinued operations in Q2, while the planned post-close repurchase includes $2.0 billion dependent on the Food Ingredients divestiture closing. The filing records $27 million of held-for-sale losses related to CitraSource.
- Cross-currency swap exposure increased in focus
- No material changes were made to the risk factors disclosed in the 2025 Form 10-K. However, the updated market-risk disclosure reports cross-currency swaps in a $194 million net liability position; a 10% dollar/euro move would change fair value by approximately $252 million.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $0.2
- Gross margin
- 43.7%
- Operating margin
- 8.1%
- Segment
- Taste: $688 million, up 5% year over year
- Segment
- Health & Biosciences: $601 million, up 8% year over year
- Segment
- Scent: $665 million, up 10% year over year
- Segment
- Pharma Solutions: $0 million, versus $103 million, following divestiture
What they said about what is next.
The 10-Q does not provide a quantitative sales, EPS, EBITDA, or cash-flow outlook. Management expects 2026 capital spending of approximately 6.0% of total company sales, versus approximately 5.5% in 2025, and expects a $500 million accelerated repurchase in the second half of 2026; the remaining $2.0 billion repurchase is expected following the Food Ingredients divestiture, with completion expected by the end of 2027.
The filing reads about the same as the one before it.
What came before.
- 10-Q · May 5, 2026
- IFF reported Q1 2026 performance with net sales of $2.741 billion, down 4% from the previous year but up 3% in constant currency when adjusting for divestitures. EPS improved to $0.66, significantly better than the loss…
- 10-K · February 27, 2026
- IFF reported full-year sales of $10.890 billion in 2025 while completing a portfolio reshaping: the company restructured Nourish into Taste and Food Ingredients effective January 1, 2025 and completed divestitures of…
- 10-Q · August 5, 2025
- IFF's Q2 2025 results show strong performance, with revenue of $2.764 billion, beating expectations and up slightly from $2.889 billion in Q2 2024. Gross margin improved to 37.3% from 37.0% year-over-year, contributing…
- 10-Q · May 6, 2025
- IFF reported Q1 net sales of $2,843,000,000 (down $56 million vs. Q1 2024) and recorded a large goodwill impairment that drove an operating loss of $903,000,000 and a net loss attributable to shareholders of…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing IFF makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever